India’s pharmaceutical industry has undergone a remarkable transformation over the past quarter-century, growing from a modest USD 3 billion in 1999-2000 to an impressive USD 55-58 billion today. With projections suggesting the sector could soar to USD 130 billion within the next five years, India’s pharmaceutical landscape is emerging as a cornerstone of the nation’s economic growth.

Ranked third globally in terms of volume, India is steadily progressing toward its ambition of becoming the “pharmacy of the world.”

Government Initiatives and Policy Support

The Indian government has been pivotal in fostering the growth of the pharmaceutical sector, primarily through the introduction of Production-Linked Incentive (PLI) schemes:

1. PLI for Key Starting Materials (KSM) and Active Pharmaceutical Ingredients (API): With an outlay of INR 69.2 billion, this initiative incentivizes domestic production of 41 crucial products, offering financial rewards starting at 20% in the early years and tapering to 5% by 2029-30.
2. PLI for Pharmaceuticals: This scheme, with a budget of INR 150 billion (USD 1.74 billion), aims to drive investment in high-value pharmaceutical manufacturing and diversify the industry’s product portfolio. Incentives range from 3% to 10% and extend until 2027-28.
3. PLI for Promoting Domestic Manufacture of Medical Devices: With an outlay of INR 34.2 billion, this program provides a 5% incentive on incremental sales, creating a low-cost production environment for medical devices.

The success of these policies is evident in a 46% rise in FDI inflows from 2021-22 to 2022-23. However, a significant challenge remains: reducing reliance on imports, particularly from China, for APIs and KSMs.

India has no dearth of pharmaceutical companies, with the largest of them being Sun Pharmaceuticals. At present, the firm is the sixth-largest manufacturer of generic pharmaceuticals, with a market cap of INR 4.36 trillion as of Nov 19, 2024. At a market cap of INR 1.54 trillion, Divi’s Labs is the second largest Indian player; the company specialises in the production of active pharmaceutical ingredients (APIs) and intermediates. Around six companies (and a seventh on the horizon) have a market cap of at least INR 1 trillion.

Challenges of Dependency on Chinese Imports

Despite government efforts, India’s dependency on Chinese imports for APIs continues to be a concern. In 2023-24, Chinese imports accounted for USD 3.6 billion—a staggering 43.45% of India’s total imports in this category. Historical factors, such as pre-1991 price controls and the dominance of Chinese producers post-liberalization, have led to the decline of domestic API manufacturing.

The pandemic underscored the risks of this dependency, prompting efforts to revive domestic API production. Notable advancements include:

• Kinvan’s Production of Clavulanic Acid: Once wholly imported, this API is now manufactured domestically.
• Aurobindo Pharma’s Penicillin G Production: Resuming production of this critical KSM marks a significant step toward reducing reliance on imports.

India’s Strengths in the Global Value Chain

India’s pharmaceutical industry contributes significantly to the global value chain through cost-effective manufacturing and innovation:

1. Vaccine Manufacturing: India supplies 62% of global vaccines and over 70% of the WHO’s vaccine stock, including Diphtheria-Pertussis-Tetanus (DPT), Bacille Calmette-Guerin (BCG), and measles vaccines.
2. Medical Consumables and Disposables: India recently became a net exporter in this category, exporting goods worth USD 1.6 billion against imports of USD 1.1 billion.
3. Generic Medicines: India’s focus on affordable healthcare solutions sets it apart from developed nations, making it a vital player in providing low-cost medicines globally.

The Role of Innovation

Innovation is emerging as a critical driver for India’s pharmaceutical growth. The 2023-24 Economic Survey highlights the importance of innovation in enhancing manufacturing efficiency and developing advanced solutions. Notable developments include:

• Global Capability Centres (GCCs): Eli Lilly’s second GCC in Hyderabad is expected to create 1,000 jobs and advance global medicine delivery.
• Joint Ventures: Partnerships like Zydus Takeda demonstrate the potential of collaborative innovation in boosting domestic and global pharmaceutical capabilities.

Seizing Opportunities in India’s Pharmaceutical Sector

India’s pharmaceutical sector presents a unique opportunity for investors and businesses. The combination of robust government support, a skilled workforce, and a focus on innovation positions India as a key player in the global pharmaceutical value chain.

However, realizing the sector’s full potential requires:

• Strategic Investments in R&D: Increased funding for innovation and technology development can strengthen India’s competitive edge.
• Public-Private Partnerships: Collaboration between domestic and international players can enhance manufacturing capabilities and accelerate the shift from imports to self-reliance.
• Gradual Reduction of Import Dependency: A well-planned transition to domestic production will minimize disruptions and stabilize markets.

India’s pharmaceutical industry is at a crossroads. By leveraging its strengths and addressing existing challenges, the nation can solidify its status as a global pharmaceutical hub. For investors and businesses, this is a golden opportunity to contribute to and benefit from one of the world’s fastest-growing industries.